Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
1.470
+0.030 (2.08%)
At close: Dec 20, 2024, 3:39 PM
1.479
+0.009 (0.64%)
After-hours: Dec 20, 2024, 7:52 PM EST
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $158.00K in the quarter ending June 30, 2024, a decrease of -19.39%. This brings the company's revenue in the last twelve months to $667.00K, down -15.89% year-over-year. In the year 2023, Can-Fite BioPharma had annual revenue of $743.00K, down -8.27%.
Revenue (ttm)
$667.00K
Revenue Growth
-15.89%
P/S Ratio
n/a
Revenue / Employee
$83,375
Employees
8
Market Cap
10.09M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
China Jo-Jo Drugstores | 154.54M |
Zhongchao | 17.41M |
Kiora Pharmaceuticals | 16.02M |
Mobile-health Network Solutions | 13.97M |
Evoke Pharma | 8.62M |
Ensysce Biosciences | 4.42M |
BioRestorative Therapies | 377.00K |
Eyenovia | 31.83K |
CANF News
- 4 weeks ago - 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 5 weeks ago - Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewsWire
- 6 weeks ago - Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia - GlobeNewsWire
- 2 months ago - Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson - GlobeNewsWire
- 2 months ago - FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer - GlobeNewsWire
- 3 months ago - Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health - GlobeNewsWire
- 4 months ago - Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies - GlobeNewsWire
- 4 months ago - OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire